HPV vaccines to prevent cervical cancer and genital warts: An update

Vaccine

Volumn 32, Issue 14, 2014, Pages 1595-1601

  Dochez, Carine ^a   Bogers, Johannes J ^a,b   Verhelst, Rita ^a,b   Rees, Helen ^c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cervical cancer; Genital warts; HPV vaccines; New developments

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT DNA; WART VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; BACTERIOPHAGE; CONDYLOMA ACUMINATUM; CROSS PROTECTION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DIZZINESS; DRUG DOSE REGIMEN; EPITHELIUM CELL; FATIGUE; FEVER; HEADACHE; HOST CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; KERATINOCYTE; MYALGIA; NAUSEA; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRAL CLEARANCE; VIRION; VIRUS CAPSID; VIRUS ENTRY; VIRUS LIKE AGENT; WART VIRUS;

CERVICAL CANCER; GENITAL WARTS; HPV VACCINES; NEW DEVELOPMENTS;

CAPSID PROTEINS; CLINICAL TRIALS AS TOPIC; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MALE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84896720902     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.081     Document Type: Article

References (82)

1. Forman D., de Martel C., Lacey C.J., Soerjomataram I., Lortet-Tieulent J., Bruni L., et al. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30 Suppl 5:F12-F23.
2. Arbyn M., Raifu A.O., Weiderpass E., Bray F., Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009, 45:2640-2648.
3. Munoz N., Bosch F.X. HPV and cervical neoplasia: review of case-control and cohort studies. The epidemiology of human papillomavirus and cervical cancer 1992, 251-261. IARC Scientific Publications No. 119, Lyon, France. N. Munoz, F.X. Bosch, K.V. Shah, A. Meheus (Eds.).
4. Walboomers J.M., Meijer C.J. Do HPV-negative cervical carcinomas exist. J Pathol 1997, 181:253-254.
5. Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., de Sanjose S., Bruni L., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26 Suppl 10:K1-K16.
6. Gissmann L., Wolnik L., Ikenberg H., Koldovsky U., Schnürch H.G. zur Hausen H Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. PNAS 1983, 80(2):560-563.
7. Aubin F., Prétet J.L., Jacquard A.C., Saunier M., Carcopino X., Jaroud F., et al. Human papillomavirus genotype distribution in external acuminata condylomata: a large French National Study (EDiTH IV). Clin Infect Dis 2008, 47(5):610-615.
8. Garland S.M., Steben M., Sings H.L., James M., Lu S., Railkar R., Barr E., Haupt R.M., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199(6):805-814.
9. Kjaer S.K., Tran T.N., Sparen P., Tryggvadottir L., Munk C., Dasbach E., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007, 196(10):1447-1454.
10. Munk C., Nielsen A., Liaw K.L., Kjaer S.K. Genital warts in men: a large population-based cross-sectional survey of Danish men. Sex Transm Infect 2012, 88(8):640-644.
11. Fenton K.A., Korovessis C., Johnson A.M., McCadden A., McManus S., Wellings K., et al. Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. Lancet 2001, 358(9296):1851-1854.
12. Dinh T.H., Sternberg M., Dunne E.F., Markowitz L.E. Genital warts among 18- to 59-year-olds in the United States: national health and nutrition examination survey, 1999-2004. Sex Transm Dis 2008, 35(4):357-360.
13. Grulich A.E., de Visser R.O., Smith A.M., Rissel C.E., Richters J. Sex in Australia: knowledge about sexually transmissible infections and blood-borne viruses in a representative sample of adults. Aust NZ J Public Health 2003, 27(2):230-233.
14. de Villiers E-M. Cross-roads in the classification of papillomaviruses. Virology 2013, 445:2-10.
15. Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J.F., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366:991-998.
16. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007, 111:145-153.
17. Denny L.A., Franceschi S., de Sanjosé S., Heard I., Moscicki A.B., Palefsky J. Human papillomavirus, human immunodeficienty virus and immunosuppression. Vaccine 2012, 30S:F168-F174.
18. Stanley M., Pinto L.A., Trimble C. Human papillomavirus vaccines-immune responses. Vaccine 2012, 30 Suppl 5:F83-F87.
19. Doorbar J., Quint W., Banks L., Bravo I.G., Stoler M., Broker T.R., et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30 Suppl 5:F55-F70.
20. Horvath C.A.J., Boulet G.A.V., Renoux V.M., Delvenne P.O., Bogers J-P.J. Mechanisms of cell entry by human papillomaviruses: an overview. Virol J 2010, 7:11.
21. Sahebali S., Van den Eynden G., Murta E.F., Michelin M.A., Cusumano P., Petignat P., et al. Stromal issues in cervical cancer: a review of the role and function of basement membrane, stroma, immune response and angiogenesis in cervical cancer development. Eur J Cancer Prev 2010, 19:204-215.
22. World Health Organization Human papillomavirus vaccines. WHO position paper. Weekly epidemiological record 2009 2009, vol. 84 (15):118-131.
23. World Health Organization The immunological basis for immunization series. Module 19: human papillomavirus infection 2011, WHO, Department of Immunization, Vaccines and Biologicals.
24. Romanowski B. Long-term protection against cervical cancer infection with the human papillomavirus. Hum Vaccines 2011, 7(2):161-169.
25. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6: 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118(5):2135-2145.
26. Petaja T., Keranen H., Karppa T., Kawa A., Lantela S., Siitari-Mattila M., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009, 44(1):33-40.
27. Dillner J., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., Hernandez-Avila M., et al. On behalf of FUTURE I/II Study Group. Four years efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial. BMJ 2010, 341:c3493.
28. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009, 374(9686):301-314.
29. Herrero R., Wacholder S., Rodrigeuz A.C., Solomon D., Gonzalez P., Kreimer A.R., et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomised clinical trial in Guanacaste, Costa Rica. Cancer Discovery 2011, 1(5):408-419.
30. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30S:F123-F138.
31. Villa L.L., Costa L.R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.-E. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.
32. Roteli-Martins C.M., Naud P., De Borba P., Teixeira J.C., De Carvalho N.S., Zahaf T., et al. Sustained immunogenicity and efficacy of the HPV-16/18 ASO4-adjuvanted vaccine. Hum Vaccines Immunother 2012, 8(3):390-397.
33. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
34. Muñoz N., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Nat Cancer Inst 2010, 102(5):325-339.
35. Fairley C.K., Hocking J.S., Gurrin L.C., Chen M.Y., Donovan B., Bradshaw C.S. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009, 85(7):499-502.
36. Read T.R., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87(7):544-547.
37. Ali H., Donovan B., Wand H., Read T.R., Regan D.G., Grulich A.E., et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013, 346:f2032.
38. Baandrup L., Blomberg M., Dehlendorff C., Sand C., Andersen K.K., Kjaer S.K. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013, 40(2):130-135.
39. Leval A., Herweijer E., Arnheim-Dahlström L., Walum H., Frans E., Sparén P., et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012, 206(6):860-866.
40. Leval A., Herweijer E., Ploner A., Eloranta S., Fridman Simard J., Dillner J., et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Nat Cancer Inst 2013, 105(7):469-474.
41. Bauer H.M., Wright G., Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012, 102(5):833-835.
42. Harper D.M., Williams K.B. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discovery Med 2010, 10(50):7-17.
43. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccines 2009, 5(10):705-719.
44. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomised study of healthy women aged 18-45 years. Hum Vaccines 2011, 7(12):1343-1358.
45. Einstein M. On behalf of the HPV-010 Study Group. Comparison of immunogenicity of two prophylactic human papillomavirus (HPV) vaccines as month 48. Int J Gynecol Obstetrics 2012, 119S3:S334.
46. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VPL vaccine formulated with the MPL/aluminium salt combination (ASO4) compared to aluminium salt only. Vaccine 2006, 24:5937-5949.
47. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007, 25(26):4931-4939.
48. McKeage K., Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix(R)): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 2011, 71(4):465-488.
49. Denny L., Hendricks B., Gordon C., Hervé C., Thomas F., Hezareh M., et al. Safety and immunogenicity of the HPV-16/18 ASO4-adjuvanted vaccine in HIV-positive women in South Africa up to 12 months after vaccination. Int J Gynecol Obstetrics 2012, 119(Supp 3):S323-S324.
50. Levin M.J., Moscicki A., Song L., Fenton T., Meyer W.A., Read J.S. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6: 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immun Defic Syndr 2010, 55(2):197-204.
51. Kemp T.J., Hildesheim A., Safaeian M., Dauner J.G., Pan Y., Porras C., et al. HPV16/18 L1 VLP vaccine induces cross-neutralising antibodies that may mediate cross-protection. Vaccine 2011, 29(11):2011-2014.
52. Malagon T., Drolet M., Boily M-C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:781-789.
53. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparison of the immunogenicty of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccines 2011, 7(12):1359-1373.
54. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV16/18 ASO4 adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomized, double blind PATRICIA trial. Lancet Oncol 2012, 13(1):100-110.
55. Dillner J., Arbyn M., Unger E., Dillner L. Monitoring of human papillomavirus vaccination. Clin Exp Immunol 2010, 163:17-25.
56. Tota J.E., Ramanakumar A.V., Jiang M., Dillner J., Walter S.D., Kaufman J.S., et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol 2013, 10.1093/aje/kwt018.
57. Kahn J.A., Brown D.R., Ding L., Widdice L.E., Shew M.L., Glynn S., et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012, 10.1542/peds. 2011-3587.
58. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M.
59. Romanowski B., Schwarz T.F., Ferguson L.M., Peters K., Dionne M., Schulze K., et al. Immunogenicity and safety of the HPV-16/18 ASO4-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule. Results from a randomized study. Hum Vaccines 2011, 7(12):1374-1386.
60. Schwarz T., Romanowski B., Peters K., Dionne M., Schulze K., Ramjattan B., et al. Immune response to the HPV-16/18 ASO4-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 3 years after vaccination. Int J Gynecol Obstetrics 2012, 119S3:S476.
61. Dobson S.R.M., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs. 3 doses in young women. JAMA 2013, 309(17):1793-1802.
62. Serrano B., Alemany L., Tous S., Bruni L., Clifford G.M., Weiss T., et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012, 7:38.
63. V503, ClinicalTrials search result.
64. Karanam B., Jagu S., Huh W.K., Roden R.B.S. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 2009, 87:287-299.
65. Tumban E., Peabody J., Peabody D.S., Chackerian B. A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine 2013, 31:4647-4654.
66. Yoon S-W., Lee T-Y., Kim S-J., Lee I-H., Sung M-H., Park J-S., et al. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Vaccine 2012, 30:3286-3294.
67. Tumban E., Peabody J., Peabody D.S., Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 2011, 6:e23310.
68. Stern P.L., van der Burg S.H., Hampson I.N., Broker T.R., Fiander A., Lacey C.J., et al. Therapy of human papillomavirus-related disease. Vaccine 2012, 30:F71-F82. Suppl 5.
69. Botha M.H., Dochez C. Introducing human papillomavirus vaccines into the health system in South Africa. Vaccine 2012, 30S:C28-C34.
70. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction-the first five years. Vaccine 2012, 30S:F139-F148.
71. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
72. Canfell K., Chesson H., Kulasingam S.L., Berkhof J., Diaz M., Kim J.J. Modeling preventative strategies against human papillomvirus-related disease in developed countries. Vaccine 2012, 30S:F157-F167.
73. Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJLM, Berkhof J, Wallinga J. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med 8(12):e1001147. doi:10.1371/journal.pmed.1001147.
74. Marty R., Roze S., Bresse X., Largeron N., Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer 2013, 13:10.
75. Australian Government. Department of health and aging. 〈〉 [cited 11 June 2013]. http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv.
76. Department of Health. Annual HPV vaccine coverage in England in 2009/2010. 〈〉 [cited 11 June 2013]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/147510/dh_123826.pdf.
77. Top G, Paeps A. HPV vaccinatie in Vlaanderen - resultaten van het eerste vaccinatiejaar 2010-2011. Infectieziektebulletin [cited 12 June 2013]. http://www.infectieziektebulletin.be/defaultSubsite.aspx%3Fid=31494%23.
78. Centers for Disease Control and Prevention Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMRW 2013, 62(29):591-595. [cited 2 September 2013]. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6229a4.htm.
79. Editorial Financing HPV vaccination in developing countries. Lancet 2011, 377(9777):1544.
80. GAVI Alliance. [cited 11 June 2013]. http://www.gavialliance.org/library/news/press-releases/2013/hpv-price-announcement/.
81. Kaddar M., Schmitt S., Makinen M., Milstien J. Global support for new vaccine implementation in middle-income countries. Vaccine 2013, 31S:B81-B96.
82. PAHO Revolving Fund Vaccine prices 2013, [cited 12 June 2013]. http://www.paho.org/hq/index.php%3Foption=com_content%26view=article%26id=1864%26Itemid=2234%26lang=en.